Tuesday, June 2, 2026
ISSN 2765-8767
  • Survey
  • Podcast
  • Write for Us
  • My Account
  • Log In
Daily Remedy
  • Home
  • Articles
  • Podcasts
    How NADAC, WAC, and ASP Shape Drug Costs

    How NADAC, WAC, and ASP Shape Drug Costs

    April 20, 2026
    The Hidden Costs Employers Don’t See in Traditional Health Plans

    The Hidden Costs Employers Don’t See in Traditional Health Plans

    March 22, 2026
    The Impact of COVID-19 on Patient Trust

    The Impact of COVID-19 on Patient Trust

    March 3, 2026
    Debunking Myths About GLP-1 Medications

    Debunking Myths About GLP-1 Medications

    February 16, 2026
    The Future of LLMs in Healthcare

    The Future of LLMs in Healthcare

    January 26, 2026
    The Future of Healthcare Consumerism

    The Future of Healthcare Consumerism

    January 22, 2026
  • Surveys

    Surveys

    Public Perception of Peptide Regulation and Compounding Practices

    Public Perception of Peptide Regulation and Compounding Practices

    April 19, 2026
    Understanding of Clinical Evidence in Peptide and Hormone Use

    Understanding of Clinical Evidence in Peptide and Hormone Use

    March 30, 2026

    Survey Results

    Can you tell when your provider does not trust you?

    Can you tell when your provider does not trust you?

    January 18, 2026
    Do you believe national polls on health issues are accurate

    National health polls: trust in healthcare system accuracy?

    May 8, 2024
    Which health policy issues matter the most to Republican voters in the primaries?

    Which health policy issues matter the most to Republican voters in the primaries?

    May 14, 2024
    How strongly do you believe that you can tell when your provider does not trust you?

    How strongly do you believe that you can tell when your provider does not trust you?

    May 7, 2024
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Official Learner
No Result
View All Result
  • Home
  • Articles
  • Podcasts
    How NADAC, WAC, and ASP Shape Drug Costs

    How NADAC, WAC, and ASP Shape Drug Costs

    April 20, 2026
    The Hidden Costs Employers Don’t See in Traditional Health Plans

    The Hidden Costs Employers Don’t See in Traditional Health Plans

    March 22, 2026
    The Impact of COVID-19 on Patient Trust

    The Impact of COVID-19 on Patient Trust

    March 3, 2026
    Debunking Myths About GLP-1 Medications

    Debunking Myths About GLP-1 Medications

    February 16, 2026
    The Future of LLMs in Healthcare

    The Future of LLMs in Healthcare

    January 26, 2026
    The Future of Healthcare Consumerism

    The Future of Healthcare Consumerism

    January 22, 2026
  • Surveys

    Surveys

    Public Perception of Peptide Regulation and Compounding Practices

    Public Perception of Peptide Regulation and Compounding Practices

    April 19, 2026
    Understanding of Clinical Evidence in Peptide and Hormone Use

    Understanding of Clinical Evidence in Peptide and Hormone Use

    March 30, 2026

    Survey Results

    Can you tell when your provider does not trust you?

    Can you tell when your provider does not trust you?

    January 18, 2026
    Do you believe national polls on health issues are accurate

    National health polls: trust in healthcare system accuracy?

    May 8, 2024
    Which health policy issues matter the most to Republican voters in the primaries?

    Which health policy issues matter the most to Republican voters in the primaries?

    May 14, 2024
    How strongly do you believe that you can tell when your provider does not trust you?

    How strongly do you believe that you can tell when your provider does not trust you?

    May 7, 2024
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Official Learner
No Result
View All Result
Daily Remedy
No Result
View All Result
Home Contrarian

Denials as a Feature, Not a Bug: How Systemic Health Insurance Practices Constitute Fraud

Investigating the Widespread and Systematic Denials in Health Insurance as Grounds for Consumer Fraud

Dr. Jay K Joshi by Dr. Jay K Joshi
February 3, 2025
in Contrarian
0

Introduction: The Hidden Strategy of Health Insurance Denials

For millions of Americans, dealing with health insurance claims is a frustrating and often financially ruinous experience. Denied claims are typically seen as bureaucratic hurdles, but data suggests something far more insidious: systemic denials are not a flaw in the system; they are a feature. This article explores how widespread claim denials by major insurers, backed by statistical evidence and expert analysis, amount to institutional fraud and consumer abuse.

The Data: How Pervasive Are Health Insurance Denials?

A 2023 report by the Kaiser Family Foundation (KFF) revealed that in 2021 alone, nearly 17% of in-network claims in Affordable Care Act (ACA) marketplace plans were denied. However, denial rates vary drastically by insurer and state. For instance:

  • UnitedHealthcare had a claim denial rate of approximately 25% in certain ACA plans.
  • Cigna and Anthem showed denial rates exceeding 20% in multiple states.
  • Medicaid managed care plans reported denial rates as high as 35% in some states.
  • Private employer-sponsored insurance plans consistently reject 10-15% of claims.

A report by the Department of Health and Human Services (HHS) in 2022 found that less than 0.2% of denied claims were appealed, revealing that insurers bank on policyholders’ inability to contest rejections effectively.

The Profit Motive: Why Insurers Benefit from Systemic Denials

Financial Incentives to Deny Claims

Health insurance companies operate on a simple profit model: the less they pay in claims, the more they profit. By embedding high denial rates into their system, they create financial barriers that dissuade patients from pursuing care. A 2020 study in the Journal of Health Economics found that insurers that consistently denied claims saw a 15-20% increase in quarterly profits compared to those with lower denial rates.

Denials and Stock Market Performance

Publicly traded insurers like Humana, UnitedHealthcare, and Aetna see direct stock price benefits from reducing claims payouts. When Humana reported a 5% reduction in claim approvals in 2022, its stock surged by 8% within weeks.

State-by-State Breakdown: Where Are the Worst Denials Happening?

Denial rates vary across the U.S., with some states exhibiting alarmingly high rejection rates:

  • California: 24% of ACA in-network claims denied
  • Texas: 29% denial rate across Medicaid managed care plans
  • New York: 18% denial rate for private insurance claims
  • Florida: 31% of hospital-related claims denied by major insurers
  • Illinois: 27% denial rate among Blue Cross Blue Shield ACA plans

A 2023 Government Accountability Office (GAO) report highlighted that insurers in states with fewer consumer protections have denial rates 10-15% higher than those with stricter regulations.

Grounds for Fraud: Why Systemic Denials Violate Consumer Protection Laws

Patterns of Deceptive Practices

Consumer protection laws prohibit deceptive business practices, yet insurance denials follow predictable, algorithmic rejection strategies that disproportionately affect policyholders in need of expensive medical interventions.

Case Study: Cigna’s Automatic Denial Algorithm
A 2023 ProPublica investigation exposed Cigna’s AI-driven claim denials, where doctors rejected claims en masse in under 1.2 seconds, flagging thousands of legitimate medical procedures as unnecessary. Cigna’s practices mirror fraudulent activity under the False Claims Act, which forbids the wrongful withholding of payments for medical services.

Legal Precedents

The Supreme Court has historically ruled against companies engaging in systematic deception. If insurance denials can be proven to follow predetermined, profit-driven strategies, insurers could face criminal fraud charges. The Federal Trade Commission (FTC) and state attorney generals have launched investigations into such cases, though large-scale legal action remains elusive.

The Human Cost: How Denials Harm Patients

Medical Debt and Financial Ruin

A 2022 survey from the Consumer Financial Protection Bureau (CFPB) found that more than 57% of medical debt in the U.S. originates from denied insurance claims. This financial burden disproportionately affects low-income families and individuals with chronic illnesses.

Delayed and Denied Care

Research from the American Medical Association (AMA) shows that 1 in 5 patients experience significant health deterioration due to claim denials. Many are forced to forego treatment, leading to preventable hospitalizations and higher long-term healthcare costs.

What Can Be Done? Investigating Insurers for Systemic Fraud

Federal and State-Level Investigations

Regulatory agencies should launch large-scale fraud investigations into insurers with high denial rates. The Department of Justice (DOJ) has the authority to pursue criminal charges under the Racketeer Influenced and Corrupt Organizations (RICO) Act if patterns of fraudulent denials can be established.

Policy Reforms

  1. Mandatory Transparency: Insurance companies must disclose real-time denial data per plan and per state.
  2. Automatic Appeals Process: Denied claims should be automatically reviewed by independent medical professionals.
  3. Consumer Right to Sue: Patients must have streamlined legal options to sue insurers for wrongful denials.

Conclusion: Systemic Denials Demand Criminal Accountability

Health insurance denials are not just unethical—they are an intentional strategy designed to maximize profits at the expense of patient care. The data is clear: systemic denials are fraud, and insurance companies must be investigated, held accountable, and reformed. If we fail to act, millions of Americans will continue to suffer from unjust rejections, medical bankruptcy, and preventable health crises.

By treating insurance denials as criminal fraud rather than mere corporate inefficiency, we can push for real accountability in a system that has, for too long, prioritized profits over patient lives.

Primary Sources:

  • Kaiser Family Foundation (KFF), 2023 Report on ACA Claim Denials
  • Department of Health and Human Services (HHS), 2022 Study on Claim Rejections
  • Journal of Health Economics, 2020 Study on Insurer Profit Margins
  • Government Accountability Office (GAO), 2023 Report on State-Level Denial Rates
  • ProPublica, 2023 Investigation into Cigna’s Automatic Denial System
  • Consumer Financial Protection Bureau (CFPB), 2022 Report on Medical Debt
  • American Medical Association (AMA), 2023 Study on Denials and Patient Outcomes
ShareTweet
Dr. Jay K Joshi

Dr. Jay K Joshi

Dr. Joshi is the founding editor of Daily Remedy

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Videos

summary

An in-depth exploration of drug pricing, including key databases like NADAC, WAC, and ASP, and how they influence the pharmaceutical supply chain, policy, and patient advocacy. The episode also introduces MedPricer's innovative pricing intelligence platform, offering valuable insights for healthcare professionals, policymakers, and patients.

Chapters

00:00 Understanding Drug Pricing Dynamics
03:52 Exploring the Drug Pricing Database
10:07 Patient Advocacy and Drug Pricing
13:56 Market Intelligence in Drug Pricing
How NADAC, WAC, and ASP Shape Drug CostsDaily Remedy
YouTube Video X-Tfwy7XKEg
Subscribe

Policy Shift in Peptide Regulation

Clinical Reads

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

by Daily Remedy
April 19, 2026
0

Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...

Read more

Join Our Newsletter!

Twitter Updates

Tweets by TheDailyRemedy

Popular

  • A man wearing a suit raising a judge's gavel beside a small model hospital building on a desk in a bright office.

    When Hospitals Can Be Liable for Abusive Providers

    0 shares
    Share 0 Tweet 0
  • Observations From the Rx & Illicit Drug Summit

    0 shares
    Share 0 Tweet 0
  • Case Analysis of Dr. Ball

    1 shares
    Share 0 Tweet 0
  • Retatrutide: The Weight Loss Drug Everyone Wants—But Can’t Officially Get

    1 shares
    Share 0 Tweet 0
  • Employers Don’t Really Care About Your Mental Health

    0 shares
    Share 0 Tweet 0
  • 628 Followers

Daily Remedy

Daily Remedy offers the best in healthcare information and healthcare editorial content. We take pride in consistently delivering only the highest quality of insight and analysis to ensure our audience is well-informed about current healthcare topics - beyond the traditional headlines.

Daily Remedy website services, content, and products are for informational purposes only. We do not provide medical advice, diagnosis, or treatment. All rights reserved.

Important Links

  • Support Us
  • About Us
  • Contact us
  • Privacy Policy
  • Terms and Conditions

Join Our Newsletter!

  • Survey
  • Podcast
  • About Us
  • Contact us

© 2026 Daily Remedy

No Result
View All Result
  • Home
  • Articles
  • Podcasts
  • Surveys
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Official Learner

© 2026 Daily Remedy